Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

SIMPLE SUMMARY: We conducted a phase II randomized placebo-controlled trial to investigate namodenoson, an A3 adenosine-receptor agonist, as 2nd-line treatment for advanced hepatocellular carcinoma and moderate hepatic dysfunction (Child–Pugh [CP] scores of 7–9). The study included 50 patients in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Stemmer, Salomon M., Manojlovic, Nebojsa S., Marinca, Mihai Vasile, Petrov, Petar, Cherciu, Nelly, Ganea, Doina, Ciuleanu, Tudor Eliade, Pusca, Ioana Adriana, Beg, Muhammad Shaalan, Purcell, William T., Croitoru, Adina-Emilia, Ilieva, Rumyana Nedyalkova, Natošević, Sladjana, Nita, Amedeia Lavinir, Kalev, Dimitar Nikolaev, Harpaz, Zivit, Farbstein, Motti, Silverman, Michael H., Bristol, David, Itzhak, Inbal, Fishman, Pnina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825785/
https://www.ncbi.nlm.nih.gov/pubmed/33430312
http://dx.doi.org/10.3390/cancers13020187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825785/
https://www.ncbi.nlm.nih.gov/pubmed/33430312
http://dx.doi.org/10.3390/cancers13020187

Ejemplares similares